Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ORG-129
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : AgomAb Therapeutics N.V
Deal Size : Undisclosed
Deal Type : Acquisition
Agomab Therapeutics to Acquire Origo Biopharma
Details : The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 28, 2021
Lead Product(s) : ORG-129
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : AgomAb Therapeutics N.V
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : ORG-129
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First in Human Study of ORG-129 in Healthy Volunteers
Details : ORG-129 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2021
Lead Product(s) : ORG-129
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
